Biosergen AB
BIOSGN | ST
Overview
Corporate Details
- ISIN(s):
- SE0016013460 (+2 more)
- LEI:
- 549300YD2OGUE7BMP925
- Country:
- Sweden
- Address:
- Fogdevreten 2, 171 65 Solna
- Website:
- https://biosergen.net/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Biosergen AB is a clinical-stage biotechnology company dedicated to developing innovative therapies for life-threatening invasive fungal infections. The company's lead candidate, BSG005, is a genetically improved, fungicidal polyene macrolide designed to offer superior safety and potency compared to existing treatments. It primarily targets immunocompromised patients, such as those with cancer, AIDS, or who are organ transplant recipients. Originating from research at the Norwegian University of Science and Technology, BSG005 has completed a Phase 1 study showing no significant side effects and has been granted Orphan Drug Designation by the U.S. FDA. The company collaborates with partners like Alkem Laboratories to advance its clinical development programs.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Biosergen AB.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| No filings match the current criteria. | ||||
Automate Your Workflow. Get a real-time feed of all Biosergen AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Biosergen AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
